Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: GlobeNewswire
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral presentation at the American Society of Hematology (ASH) 67th Annual Meeting taking place in Orlando, FL December 6-9, 2025. The abstracts can be found on the ASH 2025 website ASH Annual Meeting & Exposition - Hematology.org. “We are excited for the opportunity to share the first-time disclosure of our novel JAK2V617F mutant selective inhibitor program as well as the discovery of first-in-class CALR-targeted precision DACs delivering CDK9 degrader payloads,” stated Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude. “For JAK2, our research team made a breakthrough in the discovery of
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLDPR Newswire
- PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewswire
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
PRLD
Earnings
- 11/12/25 - Beat
PRLD
Analyst Actions
- 9/23/25 - HC Wainwright
PRLD
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 11/7/25 - Form 4
- PRLD's page on the SEC website